Vancouver BC Canada, August 14, 2024

加拿大不列颠哥伦比亚省温哥华，2024年8月14日

Virogin Biotech, a clinical-stage biotechnology company specializing in next-generation oncolytic viruses and mRNA technologies, proudly announces that its latest research on VG201, an advanced non-attenuated HSV-1 oncolytic virus product based on transcription-translation dual regulation (TTDR), has been selected for an oral presentation at the prestigious 2024 European Society for Medical Oncology (ESMO) Conference..

Virogin Biotech是一家专注于下一代溶瘤病毒和mRNA技术的临床阶段生物技术公司，它骄傲地宣布，其对VG201的最新研究，VG201是一种基于转录-翻译双重调控（TTDR）的先进非减毒HSV-1溶瘤病毒产品，已被选为2024年欧洲医学肿瘤学会（ESMO）会议的口头报告。。

This year’s ESMO Congress will be held at the Fira Barcelona Gran Via in Barcelona, Spain, from September 13 to September 17, 2024. The presentation, titled “The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads in patients with advanced solid tumors,” will unveil updated findings from VG201’s Phase I trial..

今年的ESMO大会将于2024年9月13日至17日在西班牙巴塞罗那的Fira巴塞罗那大通道举行。该演讲题为“VG2025 I期试验的最新报告，VG2025是一种在晚期实体瘤患者中表达IL-12和IL-15/Rα有效载荷的非减毒HSV-1溶瘤病毒”，将公布VG201 I期试验的最新发现。。

VG201’s preliminary results were previously presented at the 2023 ASCO and ESMO Asia conferences. The updated data to be presented at ESMO 2024 will include outcomes from 23 patients treated with VG201, with treatment durations ranging from 1 to 12 months. The study population included 13 males and 10 females, with a median age of 51.5 years (ranging from 43 to 73 years).

VG201的初步结果先前已在2023年ASCO和ESMO亚洲会议上发表。。研究人群包括13名男性和10名女性，中位年龄为51.5岁（43至73岁）。

30% of the patients had been resistant to PD(L)1 inhibitors, with over 65% having undergone at least three prior treatments. To date, 8 serious adverse events (SAEs) have been reported, none of which were related to VG201. Importantly, no treatment-related adverse events (TRAEs) led to drug reduction, treatment discontinuation, or death, and no viral shedding was observed in any samples..

30%的患者对PD（L）1抑制剂有耐药性，超过65%的患者至少接受过三次治疗。迄今为止，已经报告了8种严重不良事件（SAE），其中没有一种与VG201有关。重要的是，没有与治疗相关的不良事件（TRAEs）导致药物减少，停止治疗或死亡，并且在任何样品中均未观察到病毒脱落。。

Among the 15 evaluable patients, there were 3 partial responses (PR), including one case each of intrahepatic cholangiocarcinoma (ICC), neuroendocrine carcinoma (NEC), and breast cancer, alongside 8 cases of stable disease (SD). Tumor reduction was also observed in non-injected lesions, further underscoring VG201’s clinical safety and encouraging anti-tumor efficacy.

在15例可评估的患者中，有3例部分缓解（PR），包括肝内胆管癌（ICC），神经内分泌癌（NEC）和乳腺癌各1例，以及8例稳定疾病（SD）。在未注射的病变中也观察到肿瘤减少，进一步强调了VG201的临床安全性并鼓励了抗肿瘤功效。

These findings support continued research into VG201’s potential across multiple solid tumor indications..

这些发现支持继续研究VG201在多种实体瘤适应症中的潜力。。

VG201 received FDA IND approval in January 2022 (NCT05266612) and CDE IND approval in April 2022 (NCT05477849), initiating its Phase I clinical trials in China and the U.S. These trials are currently underway at the First Affiliated Hospital of Zhejiang University School of Medicine in China and at MD Anderson Cancer Center in the U.S..

VG201于2022年1月获得FDA IND批准（NCT05266612），并于2022年4月获得CDE IND批准（NCT05477849），在中国和美国启动了其I期临床试验。这些试验目前正在中国浙江大学医学院第一附属医院和美国MD安德森癌症中心进行。。

About ESMO:

关于ESMO：

The European Society for Medical Oncology (ESMO) Congress is one of the most influential annual meetings in the field of oncology. ESMO brings together the latest advancements in oncology research and clinical practice, fostering collaboration between laboratories and clinics to advance cancer treatment.

欧洲肿瘤内科学会（ESMO）大会是肿瘤学领域最具影响力的年度会议之一。ESMO汇集了肿瘤学研究和临床实践的最新进展，促进了实验室和诊所之间的合作，以推进癌症治疗。

The goal of the congress is to unite researchers and clinicians in pursuit of better cancer treatments and more precise medical research for the benefit of patients worldwide..

大会的目标是团结研究人员和临床医生，寻求更好的癌症治疗和更精确的医学研究，以造福全世界的患者。。

About Virogin:

关于Virogin：

Founded in 2015 in Canada, Virogin is a clinical-stage biotechnology company with dual technology platforms in next-generation oncolytic viruses and mRNA therapies. Currently, the company has three products in clinical trials in both China and the United States. Its first-generation oncolytic virus product, VG161, has received FDA Fast Track and Orphan Drug Designation for its potential in addressing unmet clinical needs in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), offering significant market potential..

Virogin于2015年在加拿大成立，是一家临床阶段生物技术公司，在下一代溶瘤病毒和mRNA疗法方面拥有双重技术平台。目前，该公司有三种产品在中国和美国进行临床试验。其第一代溶瘤病毒产品VG161因其在解决肝细胞癌（HCC）和肝内胆管癌（ICC）未满足的临床需求方面的潜力而获得FDA快速通道和孤儿药指定，具有巨大的市场潜力。。

Virogin’s proprietary HSV-1 oncolytic virus platform significantly enhances the oncolytic activity of the virus while maintaining safety, thanks to the unique transcription-translation dual regulation design. This platform also enables the delivery of multiple synergistic exogenous genes and allows for both intratumoral and intravenous administration..

由于独特的转录-翻译双重调控设计，Virogin专有的HSV-1溶瘤病毒平台显着增强了病毒的溶瘤活性，同时保持了安全性。该平台还可以传递多种协同外源基因，并允许肿瘤内和静脉内给药。。

In addition to its oncolytic virus platform, Virogin has developed an mRNA technology platform with a proprietary delivery system that supports both traditional and self-amplifying mRNA (saRNA) drug development. The company’s optimized saRNA frameworks are being explored for various therapeutic applications, including several preclinical mRNA cancer vaccine candidates..

除了溶瘤病毒平台外，Virogin还开发了一种具有专有递送系统的mRNA技术平台，该系统支持传统和自扩增mRNA（saRNA）药物开发。该公司优化的saRNA框架正在探索各种治疗应用，包括几种临床前mRNA癌症候选疫苗。。

Virogin is pioneering a combined oncolytic virus and mRNA vaccine therapy, known as the Prime-Boost approach, which leverages the complementary strengths of oncolytic viruses and mRNA vaccines to induce systemic antitumor immunity and overcome the immunosuppressive tumor microenvironment. This strategy enhances immune response by exposing more tumor antigens through oncolytic virus-mediated tumor cell lysis, offering a promising and synergistic approach to cancer immunotherapy..

Virogin开创了溶瘤病毒和mRNA疫苗联合治疗的先河，称为Prime-Boost方法，该方法利用溶瘤病毒和mRNA疫苗的互补优势诱导全身抗肿瘤免疫并克服免疫抑制性肿瘤微环境。该策略通过溶瘤病毒介导的肿瘤细胞裂解暴露更多的肿瘤抗原来增强免疫应答，为癌症免疫治疗提供了一种有前途的协同方法。。

Virogin remains committed to developing innovative oncolytic virus therapies and mRNA-based cancer immunotherapies that enhance systemic antitumor immunity for patients in need.

Virogin仍致力于开发创新的溶瘤病毒疗法和基于mRNA的癌症免疫疗法，以增强需要的患者的全身抗肿瘤免疫力。